FOLH1 and prostate carcinoma: However, it has some limitations, particularly for bone lesions, which appears a potential diagnostic limitation when using 18F-PSMA-1007 and the future perspective of recurrent prostate cancer diagnostics and therapy can also be reached by novel radionuclides and ligands.